Home » Authors » Donna Young

Donna Young

Articles

ARTICLES

Adnexus Nixes IPO Route, Opts For $430M BMS Exit

Sep. 25, 2007

Pharmaceutical giant Bristol-Myers Squibb Co. is acquiring Waltham-Mass.-based Adnexus Therapeutics Inc. for $430 million in an all-cash deal, the firms said Monday. (BioWorld Today)

Adnexus Nixes IPO Route, Opts For $430M BMS Exit

Sep. 25, 2007

Pharmaceutical giant Bristol-Myers Squibb Co. is acquiring Waltham-Mass.-based Adnexus Therapeutics Inc. for $430 million in an all-cash deal, the firms said Monday. (BioWorld Today)

Senate Joins House In Passing FDA Bill That Renews PDUFA

Sep. 24, 2007

Roche Places Hold On Trial Of Hepatitis Drug From Maxygen

Sep. 24, 2007

Roche Places Hold On Trial Of Hepatitis Drug From Maxygen

Sep. 24, 2007

Senate Joins House In Passing FDA Bill That Renews PDUFA

Sep. 24, 2007

House Passes Long-Awaited Legislation On FDA Reform

Sep. 21, 2007

House Passes Long-Awaited Legislation On FDA Reform

Sep. 21, 2007

Companies, Others Should Plan: Personalized Medicine Coming

Sep. 20, 2007

Companies, Others Should Plan: Personalized Medicine Coming

Sep. 20, 2007

View All Articles by Donna Young

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...